Whole-genome sequencing and comprehensive variant analysis of combined hepatocellular-cholangiocarcinoma, cholangiolocellular carcinoma, CK19 positive HCC, and SOX9 positive HCC

Whole-genome sequencing and comprehensive variant analysis of combined hepatocellular-cholangiocarcinoma, cholangiolocellular carcinoma, CK19 positive HCC, and SOX9 positive HCC - Whole-genome sequencing and comprehensive variant analysis of HCC with cancer stem cell features

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032493

Enrollment

600

Registered

2018-06-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases in which surgical resection for HCC were performed from Jan 2007 until Dec 2017 at Kyoto University Hospital and meet both of the conditions below. (1) 20 years or older (2) pathologically diagnosed with HCC

Exclusion criteria

Exclusion criteria: Cases in which written informed consent was not obtained

Design outcomes

Primary

Measure	Time frame
The relation between the genomic mutation and the clinicopathological features in combined hepatocellular-cholangiocarcinoma, cholangiolocellular carcinoma, CK19 positive HCC, and SOX9 positive HCC	—

Countries

Japan

Contacts

Public ContactHiroshi Kawamoto

Graduate School of Medicine, Kyoto University Department of Surgery (Division of Hepato-Biliary-Pancreatic Surgery and Transplant Surgery)

hrkawamoto@kuhp.kyoto-u.ac.jp075-751-3242

Outcome results